WallStSmart

Repro Med Systems Inc (KRMD)vsResMed Inc (RMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ResMed Inc generates 13025% more annual revenue ($5.40B vs $41.13M). RMD leads profitability with a 27.5% profit margin vs -6.4%. RMD earns a higher WallStSmart Score of 70/100 (B).

KRMD

Avoid

24

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 5.0Quality: 5.0

RMD

Strong Buy

70

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 8.7Quality: 8.3
Piotroski: 6/9Altman Z: 4.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for KRMD.

RMDUndervalued (+14.4%)

Margin of Safety

+14.4%

Fair Value

$303.30

Current Price

$226.31

$76.99 discount

UndervaluedFair: $303.30Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

KRMD1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
23.3%8/10

Revenue surging 23.3% year-over-year

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.7%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
27.5%9/10

Keeps 28 of every $100 in revenue as profit

Areas to Watch

KRMD4 concerns · Avg: 2.8/10
Price/BookValuation
11.9x4/10

Trading at 11.9x book value

Market CapQuality
$195.22M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-15.6%2/10

ROE of -15.6% — below average capital efficiency

EPS GrowthGrowth
-66.0%2/10

Earnings declined 66.0%

RMD0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : KRMD

The strongest argument for KRMD centers on Revenue Growth. Revenue growth of 23.3% demonstrates continued momentum.

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.

Bear Case : KRMD

The primary concerns for KRMD are Price/Book, Market Cap, Return on Equity.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Key Dynamics to Monitor

KRMD profiles as a growth stock while RMD is a mature play — different risk/reward profiles.

RMD carries more volatility with a beta of 0.89 — expect wider price swings.

KRMD is growing revenue faster at 23.3% — sustainability is the question.

RMD generates stronger free cash flow (311M), providing more financial flexibility.

Bottom Line

RMD scores higher overall (70/100 vs 24/100), backed by strong 27.5% margins and 11.0% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Repro Med Systems Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Repro Med Systems, Inc., doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company is headquartered in Chester, New York.

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Want to dig deeper into these stocks?